Literature DB >> 18855124

Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community.

Ariane K Kawata1, Dennis A Revicki.   

Abstract

INTRODUCTION: Symptoms and cognitive impairments of schizophrenia affect social integration and functioning. Accurate measurement is essential in evaluating treatment needs and outcomes. The Personal and Social Performance scale (PSP; Morosini et al. Acta Psychiatrica Scandinavica 101(4):323-329, 2000) is a clinical tool assessing social functioning in rehabilitation settings.
METHODS: One hundred and twenty-nine patient/informant dyads at eight US sites participated in this study. Patients were at least 18 years old, have had schizophrenia/schizoaffective disorder for one year or more, and were currently residing in the community. Informants were at least 21 years old, cared for the patient for at least one month, and had contact at least twice weekly. The PSP, Personal Evaluation of Transitions in Treatment (PETiT), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), and Quality of Life Scale (QLS) tools were completed. Analyses focused on descriptive statistics, item characteristics, reliability, and validity.
RESULTS: Patients were community-dwelling outpatients without severe difficulties. The PSP scores were well correlated with each other and related measures. Socially useful activities and personal and social relationships were the strongest indicators, suggesting separate aspects of functioning. Internal consistency reliability was adequate (alpha = 0.76). The PSP was sensitive to differences in social functioning by clinical severity.
CONCLUSIONS: The PSP suggested scale reliability and validity among outpatients. Future examination should expand validity analyses and evaluate responsiveness.

Entities:  

Mesh:

Year:  2008        PMID: 18855124     DOI: 10.1007/s11136-008-9400-z

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  26 in total

Review 1.  Epidemiology of schizophrenia: the global burden of disease and disability.

Authors:  A Jablensky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2000       Impact factor: 5.270

2.  The VADO approach in psychiatric rehabilitation: a randomized controlled trial.

Authors:  Antonella Gigantesco; Michela Vittorielli; Rosaria Pioli; Ian R H Falloon; Giuseppe Rossi; Pierluigi Morosini
Journal:  Psychiatr Serv       Date:  2006-12       Impact factor: 3.084

Review 3.  Social functioning as an outcome measure in schizophrenia studies.

Authors:  T Burns; D Patrick
Journal:  Acta Psychiatr Scand       Date:  2007-10-17       Impact factor: 6.392

4.  Time-limit tests: estimating their reliability and degree of speeding.

Authors:  L J CRONBACH; W G WARRINGTON
Journal:  Psychometrika       Date:  1951-06       Impact factor: 2.500

5.  Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

Authors:  J Kane; F Canas; M Kramer; L Ford; C Gassmann-Mayer; P Lim; M Eerdekens
Journal:  Schizophr Res       Date:  2006-11-07       Impact factor: 4.939

6.  The functional consequences of memory impairments on initial work performance in people with schizophrenia.

Authors:  G Bryson; M D Bell; E Kaplan; T Greig
Journal:  J Nerv Ment Dis       Date:  1998-10       Impact factor: 2.254

7.  Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.

Authors:  Michael Davidson; Robin Emsley; Michelle Kramer; Lisa Ford; Guohua Pan; Pilar Lim; Mariëlle Eerdekens
Journal:  Schizophr Res       Date:  2007-04-26       Impact factor: 4.939

8.  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.

Authors:  D A Regier; W E Narrow; D S Rae; R W Manderscheid; B Z Locke; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1993-02

9.  Global assessment of functioning. A modified scale.

Authors:  R C Hall
Journal:  Psychosomatics       Date:  1995 May-Jun       Impact factor: 2.386

10.  Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

Authors:  Stephen R Marder; Michelle Kramer; Lisa Ford; Els Eerdekens; Pilar Lim; Mariëlle Eerdekens; Adam Lowy
Journal:  Biol Psychiatry       Date:  2007-06-28       Impact factor: 13.382

View more
  20 in total

1.  Predictors of work and education among people with severe mental illness who participated in the Danish individual placement and support study: findings from a randomized clinical trial.

Authors:  Thomas Nordahl Christensen; Iben Gammelgård Wallstrøm; Anders Bo Bojesen; Merete Nordentoft; Lene Falgaard Eplov
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-05-25       Impact factor: 4.328

2.  The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients.

Authors:  Sofia Brissos; Filipa Palhavã; João Gama Marques; Susana Mexia; Ana Lisa Carmo; Manuel Carvalho; Cátia Dias; João Data Franco; Rita Mendes; Pedro Zuzarte; Ana Isabel Carita; Andrew Molodynski; Maria Luisa Figueira
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-07-08       Impact factor: 4.328

3.  Cognitive Behavioral Therapy for Psychosis (CBT-p) Delivered in a Community Mental Health Setting: A Case Comparison of Clients Receiving CBT Informed Strategies by Case Managers Prior to Therapy.

Authors:  Harry J Sivec; Vicki L Montesano; David Skubby; Kristen A Knepp; Mark R Munetz
Journal:  Community Ment Health J       Date:  2015-08-23

Review 4.  The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

5.  Defining Occupational Competence and Occupational Identity in the Context of Recovery in Schizophrenia.

Authors:  Bhing-Leet Tan; Madeline Wei Zhen Lim; Huiting Xie; Ziqiang Li; Jimmy Lee
Journal:  Am J Occup Ther       Date:  2020 Jul/Aug

6.  Outcome prediction with a social cognitive battery: a multicenter longitudinal study.

Authors:  Eric Brunet-Gouet; Capucine Decaix-Tisserand; Mathieu Urbach; Nadine Bazin; Bruno Aouizerate; Lore Brunel; Delphine Capdevielle; Isabelle Chereau; Caroline Dubertret; Julien Dubreucq; Guillaume Fond; Christophe Lançon; Sylvain Leignier; Jasmina Mallet; David Misdrahi; Sylvie Pires; Priscille Schneider; Franck Schurhoff; Hanan Yazbek; Anna Zinetti-Bertschy; Christine Passerieux; Paul Roux
Journal:  NPJ Schizophr       Date:  2021-05-26

7.  The importance of measuring psychosocial functioning in schizophrenia.

Authors:  Sofia Brissos; Andrew Molodynski; Vasco Videira Dias; Maria Luísa Figueira
Journal:  Ann Gen Psychiatry       Date:  2011-06-24       Impact factor: 3.455

8.  Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.

Authors:  Min-Wei Huang; Tsung-Tsair Yang; Po-Ren Ten; Po-Wen Su; Bo-Jian Wu; Chin-Hong Chan; Tsuo-Hung Lan; I-Chao Liu; Wei-Cheh Chiu; Chun-Ying Li; Kuo-Sheng Cheng; Yu-Chi Yeh
Journal:  BMC Clin Pharmacol       Date:  2012-01-06

9.  Individual Placement and Support supplemented with cognitive remediation and work-related social skills training in Denmark: study protocol for a randomized controlled trial.

Authors:  Thomas Nordahl Christensen; Iben Gammelgaard Nielsen; Elsebeth Stenager; Britt Reuter Morthorst; Jane Lindschou; Merete Nordentoft; Lene Falgaard Eplov
Journal:  Trials       Date:  2015-06-21       Impact factor: 2.279

10.  Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile.

Authors:  Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-01       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.